Hematologic Malignancies Clinical Trial
Official title:
Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)Cells After Allogeneic Stem Cell Transplantation
The purpose of the Phase IIA study are to:
1. define the safety profile
2. evaluate the efficacy of a sequential infusion of unmanipulated Donor Lymphocyte
Infusions (DLI) and Cytokine Induced Killer (CIK) cells for the treatment of molecular,
cytogenetic or hematologic relapse after hematopoietic stem cell transplantation and The
progression free survival and the overall survival after the sequential infusion of
Donor Lymphocyte Infusions (DLI) and Cytokine Induced Killer(CIK) cells.
This study is an open-label, multicenter, exploratory phase IIA study to evaluate the safety
(dose-finding) and efficacy of a sequential administration of donor derived unmanipulated DLI
and in vitro expanded Cytokine Induced Killer(CIK) cells.
Two infusions of unmanipulated donor lymphocytes (1x106/Kg each) will be given with a minimum
interval of 3 weeks. Three infusions of donor Cytokine Induced Killer (CIK) cells will be
administered according to a dose escalating program, starting 3 weeks after second Donor
Lymphocyte Infusions (DLI). In presence of grade 2 or more acute graft versus host
disease(GVHD), the patient will not receive the next scheduled infusion. Only grade 4 acute
graft versus host disease (aGVHD) is considered for the dose limiting toxicity (DLT). Once
identified the maximally tolerated dose (MTD), this same combination of doses will be
administered up to 24 patients in a two-stage minimax design.
Primary Endpoints
The primary endpoints of the Phase IIA study are:
1. the Maximally Tolerated Dose (MTD) - (safety end-point)
2. the cumulative incidence of molecular, karyotypic or haematologic responses at day +100
after the end of the cell therapy program - (efficacy end-point)
Secondary Endpoints Progression Free Survival (PFS) Progression Free Survival (PFS) will be
defined as any evidence of molecular, cytogenetic or haematologic disease progression.
Cytogenetic and/or molecular relapse will be defined where available as any evidence of a
pre-transplant defined abnormality using conventional cytogenetics or FISH techniques or
molecular probes. Assessments will be performed at 1 year after the end of the cell therapy
program Overall Survival (OS) The Overall Survival(OS) will be assessed by 1 year after the
end of the cell therapy program. For assessment of the Overall Survival (OS), events will be
deaths for any causes, patients being censored if alive.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05433090 -
An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
|
N/A | |
| Completed |
NCT00061620 -
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
|
Phase 1 | |
| Enrolling by invitation |
NCT02473757 -
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
|
||
| Not yet recruiting |
NCT06296368 -
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
|
N/A | |
| Recruiting |
NCT02032446 -
Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02884375 -
Elderly CAncer Patient
|
N/A | |
| Recruiting |
NCT01203722 -
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00780052 -
Infusional C-myb ASODN in Advanced Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04098393 -
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
|
Phase 1 | |
| Recruiting |
NCT06028828 -
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
| Completed |
NCT04538599 -
RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT03609827 -
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
| Completed |
NCT01380756 -
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05849207 -
Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant
|
Phase 1 | |
| Not yet recruiting |
NCT05028478 -
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02494258 -
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
|
Phase 2 | |
| Completed |
NCT03212560 -
Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
|
||
| Active, not recruiting |
NCT02600208 -
Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device
|
Phase 2/Phase 3 | |
| Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT01949545 -
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
|
Phase 1 |